Overview

Detailed Summary

Venus Remedies Ltd is a pharmaceutical company specializing in injectables and intravenous supplies with global reach through WHO-GMP certified facilities.
In recent years, the company has had notable product launches, including the innovative anti-cancer drug 'Docetaxel' in Europe and 'Cytomib,' a treatment for blood cancer.
Venus Remedies has been expanding its consumer healthcare product line, notably launching R3SET, a pain management solution, in 2021-22.
The company has focused on process automation and business intelligence, adopting systems such as retail billing automation and implementing a BI tool like Tableau for decision-making.
Recent advancements in their R&D efforts include the launch of ELORES, an antibiotic that tackles superbugs, significantly strengthening its product portfolio.

Sector: Pharmaceuticals
Industry: Pharmaceuticals - I V Fluids
Market Cap: 941 Cr
Volatility: Moderate Risk
P/E Ratio: 12.5
Industry P/E: 12.3
PEG Ratio: —
P/B Ratio: 1.6
52W High: 872.80
52W Low: 277.85

Sales CAGR

1Y: 7.72%
3Y: 3.50%
5Y: 14.83%
10Y: 5.27%

Profit CAGR

1Y: 59.04%
3Y: 2.38%
5Y: —
10Y: 52.14%

ROE

TTM: 10.66%
3Y: 6.65%
5Y: 8.63%
10Y: 2.82%

ROCE

TTM: 13.99%
3Y: 9.40%
5Y: 9.77%
10Y: 6.06%

Technicals

‌

Forecasts

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
BAJAJHCARE	319.75	1,011 Cr	20.71	2.08	0.31	10.52	10.52	5.94
FERMENTA	326.90	958 Cr	10.89	2.45	0.76	28.46	27.38	13.04
VENUSREM	714.00	941 Cr	12.51	1.58	0.00	10.66	13.99	9.93
WANBURY	250.00	874 Cr	21.07	11.28	0.00	51.51	27.98	10.39
FREDUN	1531.00	823 Cr	23.16	3.46	0.04	22.85	26.16	7.04
ACCENTMIC	343.00	823 Cr	21.83	3.51	0.29	13.89	19.49	12.00
ANUHPHR	77.00	774 Cr	18.44	2.37	0.97	11.84	15.90	8.22

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	168	143	195	109	167	177	195	132	193	180
Expenses	150	131	176	97	163	159	166	122	162	143
Operating Profit	18	12	19	11	4.92	18	29	10	31	38
OPM %	10.61	8.36	9.98	10.37	2.94	10.38	14.87	7.66	16.06	20.81
Other Income	3.05	2.35	3.92	1.59	11	12	6.76	8.69	1.71	2.52
Interest	0.06	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.01	0.01
Depreciation	6.44	6.54	5.91	5.98	6.41	5.41	4.71	6.18	6.17	6.56
Profit Before Tax	14	7.78	17	6.85	9.07	25	31	13	26	33
Tax %	30.68	11.95	39.81	82.19	61.30	21.22	32.35	23.81	24.01	23.57
Net Profit	9.94	6.85	11	1.22	3.51	20	21	9.60	20	26
EPS in Rs	7.44	5.13	7.86	0.92	2.63	14.66	15.71	7.18	15.06	19.14

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	400	372	322	339	548	600	556	601	648	671
Expenses	349	333	289	299	494	538	495	542	584	609
Operating Profit	51	39	33	41	54	62	60	60	64	62
OPM %	12.68	10.60	10.10	12.03	9.81	10.35	10.81	9.91	9.81	9.29
Other Income	2.27	2.25	-2.87	-3.50	43	8.31	10	12	31	38
Interest	34	35	25	13	13	0.48	0.12	0.09	0.07	0.05
Depreciation	40	34	34	32	35	34	32	26	23	23
Profit Before Tax	-22	-28	-30	-8.04	49	36	38	45	72	78
Tax %	21.06	-11.48	3.87	-24.44	-27.21	-11.85	29.96	36.18	36.91	30.78
Net Profit	-17	-31	-29	-10.00	62	41	27	28	45	54
EPS in Rs	—	—	-21.37	-4.73	46.20	30.57	19.88	21.31	33.92	57.09
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	11	12	12	12	12	12	13	13	13	13
Reserves	426	376	350	320	311	388	427	447	474	548
Borrowings	314	281	259	229	158	51	43	42	41	1.69
Other Liabilities	91	95	130	171	163	104	97	98	98	153
Total Liabilities	843	765	751	733	644	556	580	601	627	716
Fixed Assets	452	406	389	364	289	262	241	216	219	229
CWIP	80	66	65	65	25	25	25	26	21	26
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20	19	84
Other Assets	310	293	297	304	330	269	314	339	368	376
Total Assets	843	765	751	733	644	556	580	601	627	716

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	47	59	31	45	78	132	41	37	37	86
Cash from Investing Activity	2.92	-18	8.46	-11	-4.75	56	-17	-51	-7.21	-76
Cash from Financing Activity	-46	-44	-39	-35	-73	-162	-9.48	-0.57	-1.08	-1.02
Net Cash Flow	3.46	-3.51	0.42	-1.17	-0.15	26	15	-15	29	9.18

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%
FIIs	1.00%	0.98%	1.03%	1.59%	1.48%	1.06%	1.18%	1.11%	1.34%	2.24%	1.86%	2.26%
DIIs	0.15%	0.15%	0.15%	0.15%	0.15%	0.15%	0.15%	0.00%	0.00%	0.11%	0.75%	1.03%
Public	57.09%	57.11%	57.07%	56.50%	56.61%	57.03%	56.91%	57.13%	56.90%	55.89%	55.63%	54.96%
Total Shareholders	21,719	20,498	19,267	19,560	19,913	19,614	19,557	19,771	19,982	19,307	17,725	18,606

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Promoter Restructuring

5 days ago

Promoter Group Amalgamation Approved (Sunev into Spine)

Boards of Sunev Pharma Solutions Pvt Ltd and Spine Software Systems Pvt Ltd approved a Scheme of Amalgamation to merge Sunev into Spine (subject to approvals); Sunev’s 17.21% stake will vest in Spine; internal restructure, no change in company control; Venus Remedies not party to the scheme.

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Venus Remedies Ltd

Venus Remedies Ltd (VENUSREM) is currently trading at 714.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Venus Remedies Ltd is a pharmaceutical company specializing in injectables and intravenous supplies with global reach through WHO-GMP certified facilities. In recent years, the company has had notable product launches, including the innovative anti-cancer drug 'Docetaxel' in Europe and 'Cytomib,' a treatment for blood cancer. Venus Remedies has been expanding its consumer healthcare product line, notably launching R3SET, a pain management solution, in 2021-22. The company has focused on process automation and business intelligence, adopting systems such as retail billing automation and implementing a BI tool like Tableau for decision-making. Recent advancements in their R&D efforts include the launch of ELORES, an antibiotic that tackles superbugs, significantly strengthening its product portfolio.

Over the past 52 weeks, Venus Remedies Ltd has traded between a low of ₹277.85 and a high of ₹872.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Venus Remedies Ltd has a market capitalization of approximately 940.77. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Venus Remedies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 12.51 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 940.77 Cr, Venus Remedies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Venus Remedies Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Venus Remedies Ltd is 12.51. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Venus Remedies Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Unlock Premium Features

Upgrade

Peers

Price Chart Comparison